Indolent Systemic
Mastocytosis

ISM is a rare and potentially debilitating mast cell disease,1,2 mainly driven by the KIT D816V mutation3,4

Patients with ISM can suffer from a wide range of symptoms, and impaired quality of life and functioning beyond objective changes1,2,5

Drawing of a fictional patient’s medical file in a folder

Patients with ISM suffer from a wide range of symptoms despite current care:6

Graph indicating symptoms of ISM based on a Dutch cohort of 164

Based on a Dutch cohort of 164 patients with ISM.

Patients with ISM suffer disrupted quality of life despite current care1,5,7

Results from the PRISM Europe survey showed:5

Graph indicating symptoms of ISM based on a Dutch cohort of 164

*The reported values reflect the range observed across countries (Italy [n=201], Germany [n=122], UK [n=110], Austria [n=63], France [n=52], Switzerland [n=44] and Spain [n=19]). HCPs scored each statement on a 1–5 scale with the following items: A great deal; Quite a bit; Somewhat; A little bit; Not at all.
**Data based on 237 patients with an ISM diagnosis who participated in the PRISM patient survey.
†Please note that these numbers represent the summed values of specific underlying scores. Patients scored each statement on a 1–5 scale with the following items: Yes, frequently part-time; Yes, frequently unemployed; Yes, frequently dismissed; No; Unsure.

Icon of a magnifying glass

Click here to learn more about AYVAKYT

About AYVAKYT

HCP=healthcare professional; ISM=indolent systemic mastocytosis

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the product SmPC for how to report adverse reactions.1

References

  1. Gotlib J, et al. NEJM Evid. 2023;2(6):EVIDoa2200339.
  2. Mesa RA, et al. Cancer. 2022;128(20):3700–3708.
  3. Muñoz-González JI, et al. Blood. 2019;134(5):456–468.
  4. Ungerstedt J, et al. Cancers. 2022;14(16):3942.
  5. Triggiani M, et al. Clin Exp Allergy. 2025;55(9):784–794.
  6. van Anrooj B, et al. Allergy. 2016;71(11):1585–1593.
  7. Kurtin S, et al. J Adv Pract Oncol. 2025:1-11.

We use cookies that are strictly necessary to operate this website. We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website, and to give you the best possible user experience. By clicking on the “Reject All Cookies" button, you understand that strictly necessary cookies will continue to be deployed for the operation of this website. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your cookies settings. You can also “Accept All Cookies" or customise your cookies settings by clicking on the buttons provided below. Click “Cookie Settings” to update your personal cookie preferences or review our Privacy Policy.

To top